Drägerwerk AG & Co. KGaA/€DRW8

05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co. KGaA, headquartered in Lübeck, Germany, operates in the medical and safety technology industries. The company's core business revolves around the production of medical equipment such as anesthesia workstations, ventilators, and patient monitoring systems, as well as safety products including personal protective equipment and gas detection technology. Founded in 1889, Drägerwerk has a substantial international presence, with markets across Europe, the Americas, Asia-Pacific, and Africa. The company's competitive strength lies in its longstanding expertise in combining engineering with innovation to meet complex regulatory and operational demands in healthcare and industrial safety sectors.

Ticker

€DRW8

Primary listing

XETRA

Industry

Health Care Equipment & Supplies
Headquarters

Employees

16,615

ISIN

DE0005550602

DRW8 Metrics

BasicAdvanced
€1.1B
-
-
0.38
€1.97
3.56%

Bulls say / Bears say

Drägerwerk AG & Co. KGaA reported a significant increase in net sales for fiscal year 2023, growing by approximately 13% to €3,373.5 million, indicating strong market demand and operational efficiency. (finanzwire.com)
The company improved its earnings before interest and taxes (EBIT) to around €166 million in 2023, a substantial rise from the previous year's negative results, showcasing effective cost management and profitability enhancement. (finanzwire.com)
Drägerwerk increased its dividend for 2023 to €1.74 per common share and €1.80 per preferred share, reflecting confidence in its financial health and commitment to shareholder returns. (finanzwire.com)
In the first quarter of 2025, Drägerwerk's EBIT plummeted from €15.1 million in the previous year to €0.4 million, attributed to lower sales volumes and higher costs, raising concerns about short-term profitability. (marketscreener.com)
The medical division experienced a decline in net sales by 2.6% (net of currency effects) to around €1,900 million in 2024, primarily due to challenging market conditions in China, indicating potential regional vulnerabilities. (marketscreener.com)
Despite a positive outlook, Drägerwerk's forecast for 2024 anticipates a modest net sales increase of 1.0 to 5.0% and an EBIT margin of 2.5 to 5.5%, suggesting limited growth potential in the near term. (finanzwire.com)
Data summarised monthly by Lightyear AI. Last updated on 28 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.

Buy €DRW8

Sign up or log in to buy
Capital at risk
Extended hours trading

Upcoming events

No upcoming events
FAQs